Aviagen Limited has reported a strong set of results for the year to 30 June 2025, underlining continued demand for poultry breeding stock despite ongoing disease pressures. The business recorded turnover of £297 million, up 24.4%, while operating profit rose to £128 million from £101 million the previous year. Growth was driven by solid product performance and continued investment in breeding and global supply.
For the farming sector, the figures highlight resilience in the poultry supply chain at a time when avian influenza continues to disrupt trade. Aviagen said some sales were lost due to disease-related restrictions, but strict biosecurity measures and the strategic spread of UK facilities helped limit the impact.
Costs remain a key pressure point. The company reported research and development spending of more than £37 million, alongside rising energy, feed and general inflationary costs. It has used forward-buying strategies to manage volatility.
Looking ahead, Aviagen has committed to further expansion under its 2025-2027 business plan. Investment is already under way in upgraded pedigree facilities and new farm developments, with £6.5 million in capital commitments earmarked for new builds.
Directors said the business remains financially strong and well placed to support farmers worldwide, with confidence in both cashflow and the longer-term outlook for the poultry sector.